667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS
Allison M. Bock(Mayo Clinic), Saira Ahmed(The University of Texas MD Anderson Cancer Center), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), R. Merryman(Dana-Farber Cancer Institute), Alex F. Herrera(City of Hope), Shakthi Bhaskar(Vanderbilt University Medical Center), Kelly Glazer Baron(University of Utah), Lei Feng(Ministry of Public Security of the People's Republic of China), Amy Ayers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Sheela Godbole(The Ohio State University Wexner Medical Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Andrew Jallouk(Vanderbilt University Medical Center), M. Lunning(University of Nebraska Medical Center), Christopher R. D’Angelo(Susan Thompson Buffett Foundation)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
|The American Journal of Medicine|2015|740
Cognitive Frailty and Adverse Health Outcomes: Findings From the Singapore Longitudinal Ageing Studies (SLAS)
|Journal of the American Medical Directors Association|2016|292
SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis
|Journal of Translational Medicine|2021|268
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263